The present study evaluated the basal DNA damage and the cellular response to this damage induced by in vitro administration of Etoposide in lymphocytes donated by twenty untreated breast cancer (BC) patients and twenty age-matched healthy women. Micronucleus (MN) and alkaline Comet assays were performed in cultured peripheral blood lymphocytes (PBL) according to a standard protocol for in vitro treatment with various concentrations of Etoposide or a control. For the Comet Assay, three samples of cells were collected: T(0) (immediately preceding treatment of the cultures), T(1) (immediately after completion of the treatment) and T(2) (four hours after completion of the treatment). MN frequency in the BC group treated with 25 muM Etoposide (19.1 +/- 7.35) was significantly higher than the control (10.9 +/- 9.87) group. In the alkaline Comet Assay, both the BC group and the healthy women showed the ability to repair Etoposide-induced DNA damage within 4 hours of reincubation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773585PMC

Publication Analysis

Top Keywords

dna damage
12
healthy women
12
repair etoposide-induced
8
etoposide-induced dna
8
breast cancer
8
cancer patients
8
alkaline comet
8
comet assay
8
completion treatment
8
dna
4

Similar Publications

Progress in the Study of TAp73 and Sperm Apoptosis.

Cell Biochem Funct

January 2025

Department of Physiology and Pharmacology, Anhui University of Chinese Medicine, Hefei, Anhui, China.

The study of the mechanism of oligoasthenospermia, which is a major cause of male infertility, has been the focus of research in the field of male reproduction. TAp73, a member of the p53 family of oncogenes, is endowed with tumor-suppressing activity due to its structural and functional homology with p53. It has been found that TAp73, plays a key role in spermatogenesis and maintaining male reproduction.

View Article and Find Full Text PDF

Objective: Cervical cancer is a common malignancy among women, and radiotherapy remains a primary treatment modality across all disease stages. However, resistance to radiotherapy frequently results in treatment failure, highlighting the need to identify novel therapeutic targets to improve clinical outcomes.

Methods: The expression of molecule interacting with CasL-2 (MICAL2) was confirmed in cervical cancer tissues and cell lines through western blotting (WB) and immunohistochemistry (IHC).

View Article and Find Full Text PDF

The p53 protein is regarded as the "Guardian of the Genome," but its mutation is tumor progression and present in more than half of malignant tumors. The pro-metastatic property of mutant p53 makes a strong argument for targeting mutant p53 with new therapeutic strategies. However, mutant p53 was considered as a challenging target for drug discovery due to the lack of small molecular binding pockets.

View Article and Find Full Text PDF

Dinotefuran (DIN) is toxic to non-target organisms and accelerates the evolution of antibiotic resistance, which poses a problem for the stable operation of the activated sludge process in wastewater treatment plants (WWTPs). However, the emergence and the transfer mechanism of antibiotic resistance genes (ARGs) in activated sludge systems under DIN stress remains unclear. Thus, in the study, the potential impact of DIN on ARGs and virulence factor genes (VFGs) in aerobic granular sludge (AGS) was investigated in depth using metagenomic binning and functional modules.

View Article and Find Full Text PDF

The disorders of glucose and lipid metabolism contribute to severe diseases, including cardiovascular disease, diabetes, and fatty liver. Here, we identified DNA damage-binding protein 2 (DDB2), an E3 ubiquitin ligase, as a pivotal regulator of lipid metabolism disorders in type II diabetes mellitus (T2DM). A mouse model of T2DM and primary mouse hepatocytes with steatosis were induced.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!